title: Brown Norway rat model of food allergy: effect of plant components on the development of oral sensitization.
abstract: The Brown Norway (BN) rat was examined as a model for investigating factors that influence the development of food allergy. An antigen dose-response curve for the production of antigen-specific reaginic antibody (IgE) induced through the oral route was determined. Animals were dosed orally with 1.0, 2.5, 5.0, 7.5, 10.0 and 12.0 mg ovalbumin/ml (0.5 ml/100 g twice a week for 6 wk). To promote IgE production the adjuvant carrageenan was administered once a week by the i.p. route. The effect on oral sensitization of 1.5 mg Gypsophila sp. saponin/ml administered together with the antigen on oral sensitization was examined in animals treated with 2.5, 6.0 or 10.0 mg ovalbumin/ml. The number of animals producing antigen specific reaginic antibody in response to 2.5 mg ovalbumin/ml was significantly increased (P < 0.01) in the group that received saponin with 2.5 mg ovalbumin/ml. These studies indicate that the BN rat is a sensitive model for the investigation of allergic reactions to food and has the potential to determine the impact of other dietary factors on the development of oral sensitization.
authors.affiliation: BIBRA International, Carshalton, Surrey, UK.
authors.forename: H A
authors.initials: HA
authors.lastname: Atkinson
authors.forename: I T
authors.initials: IT
authors.lastname: Johnson
authors.forename: J M
authors.initials: JM
authors.lastname: Gee
authors.forename: F
authors.initials: F
authors.lastname: Grigoriadou
authors.forename: K
authors.initials: K
authors.lastname: Miller
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000284:Administration, Oral; D000818:Animals; D002351:Carrageenan / Q000008:administration & dosage / Q000276:immunology; D004195:Disease Models, Animal; D004306:Dose-Response Relationship, Immunologic; D005119:Extravasation of Diagnostic and Therapeutic Materials; D005512:Food Hypersensitivity / Q000209:etiology* / Q000276:immunology; D018928:Immunity, Mucosal; D007073:Immunoglobulin E / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D007274:Injections, Intraperitoneal; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects; D019684:Magnoliopsida; D008297:Male; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology* / Q000493:pharmacokinetics; D010539:Permeability / Q000187:drug effects; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D011914:Rats, Inbred BN; D017207:Rats, Sprague-Dawley; D012503:Saponins / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000276:Adjuvants, Immunologic; D007074:Immunoglobulin G; D010936:Plant Extracts; D012503:Saponins; D007073:Immunoglobulin E; D002351:Carrageenan; D010047:Ovalbumin